The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
The acquisition will strengthen Lupin’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Ind-Ra expects revenue growth of over 12% in 2022.
Flattish volume growth and subdued new launches were key factors for last month
Subscribe To Our Newsletter & Stay Updated
